Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can training and alerts get more people on PrEP?

NCT ID NCT06334341

NEW Prevention Sponsor: Henry Ford Health System Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers at Henry Ford Health System are testing whether a mix of provider training, electronic health record alerts, HIV risk assessments, and patient videos can increase new PrEP prescriptions in primary care. The trial enrolls primary care providers and patients who meet the criteria for PrEP. Clinics are randomly assigned to receive different combinations of these tools, and the main measure is the rate of new PrEP prescriptions at each clinic.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A package of provider and patient interventions: computer-based simulation training, electronic health record alerts, HIV risk assessment, and a PrEP informational video
What this could lead to
If the strategy works, it could give primary care clinics a practical way to raise PrEP prescriptions and narrow racial and ethnic gaps in HIV prevention.
What could go wrong
The trial tests clinic-level prescription rates, not whether HIV infections fall. Results may not transfer to clinics with different resources or patient populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,380 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provider:≥ 18-years old * Provider: employed at HFH as a primary care provider * Provider: eligible to write prescriptions in the state of Michigan * Patient: ≥ 18 years old * Patient: have an appointment with a Henry Ford primary care clinic during the study period * Patient: have an EHR account * Patient: meet the indications for PrEP Exclusion Criteria: * Provider: not a HFH primary care provider * Provider: does not have prescribing privileges in the state of Michigan * Patient: currently prescribed or taking PrEP * Patient: living with HIV

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV seropositivity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV Seropositivity HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV seropositivity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Henry Ford Health

    Detroit, Michigan, 48202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.